Structure Therapeutics as a value takeover target
The panel argued that Structure Therapeutics presents value and is a likely takeover candidate following recent sector volatility, despite mixed trial data.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.